4.7 Article

Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival

期刊

GENOME MEDICINE
卷 3, 期 -, 页码 -

出版社

BIOMED CENTRAL LTD
DOI: 10.1186/gm248

关键词

-

资金

  1. Research Council at Rikshospitalet-Radiumhospitalet Health Enterprise
  2. Norwegian Cancer Society
  3. Norwegian Cancer Society [PR-2006-0442, PR-2007-0166]

向作者/读者索取更多资源

Background: Colorectal cancer (CRC) is a heterogeneous disease that, on the molecular level, can be characterized by inherent genomic instabilities; chromosome instability and microsatellite instability. In the present study we analyze genome-wide disruption of pre-mRNA splicing, and propose transcriptome instability as a characteristic that is analogous to genomic instability on the transcriptome level. Methods: Exon microarray profiles from two independent series including a total of 160 CRCs were investigated for their relative amounts of exon usage differences. Each exon in each sample was assigned an alternative splicing score calculated by the FIRMA algorithm. Amounts of deviating exon usage per sample were derived from exons with extreme splicing scores. Results: There was great heterogeneity within both series in terms of sample-wise amounts of deviating exon usage. This was strongly associated with the expression levels of approximately half of 280 splicing factors (54% and 48% of splicing factors were significantly correlated to deviating exon usage amounts in the two series). Samples with high or low amounts of deviating exon usage, associated with overall transcriptome instability, were almost completely separated into their respective groups by hierarchical clustering analysis of splicing factor expression levels in both sample series. Samples showing a preferential tendency towards deviating exon skipping or inclusion were associated with skewed transcriptome instability. There were significant associations between transcriptome instability and reduced patient survival in both sample series. In the test series, patients with skewed transcriptome instability showed the strongest prognostic association (P = 0.001), while a combination of the two characteristics showed the strongest association with poor survival in the validation series (P = 0.03). Conclusions: We have described transcriptome instability as a characteristic of CRC. This transcriptome instability has associations with splicing factor expression levels and poor patient survival.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability

Bjornar T. B. Flatin, Hege Marie Vedeld, Rita Pinto, Jonas Langerud, Guro E. Lind, Ragnhild A. Lothe, Anita Sveen, Marine Jeanmougin

Summary: Intratumor heterogeneity of colorectal cancers (CRCs) is mainly reflected in the genomic and epigenomic levels. Our study revealed that CIMP status in primary CRCs is consistent, although spatial discrepancies in individual genes indicate the potential of large-scale analysis of multiregional samples to identify robust CIMP markers for intratumor heterogeneity.

INTERNATIONAL JOURNAL OF CANCER (2021)

Article Multidisciplinary Sciences

Identification of 22 susceptibility loci associated with testicular germ cell tumors

John Pluta, Louise C. Pyle, Kevin T. Nead, Rona Wilf, Mingyao Li, Nandita Mitra, Benita Weathers, Kurt D'Andrea, Kristian Almstrup, Lynn Anson-Cartwright, Javier Benitez, Christopher D. Brown, Stephen Chanock, Chu Chen, Victoria K. Cortessis, Alberto Ferlin, Carlo Foresta, Marija Gamulin, Jourik A. Gietema, Chiara Grasso, Mark H. Greene, Tom Grotmol, Robert J. Hamilton, Trine B. Haugen, Russ Hauser, Michelle A. T. Hildebrandt, Matthew E. Johnson, Robert Karlsson, Lambertus A. Kiemeney, Davor Lessel, Ragnhild A. Lothe, Jennifer T. Loud, Chey Loveday, Paloma Martin-Gimeno, Coby Meijer, Jeremie Nsengimana, David I. Quinn, Thorunn Rafnar, Shweta Ramdas, Lorenzo Richiardi, Rolf I. Skotheim, Kari Stefansson, Clare Turnbull, David J. Vaughn, Fredrik Wiklund, Xifeng Wu, Daphne Yang, Tongzhang Zheng, Andrew D. Wells, Struan F. A. Grant, Ewa Rajpert-De Meyts, Stephen M. Schwartz, D. Timothy Bishop, Katherine A. McGlynn, Peter A. Kanetsky, Katherine L. Nathanson

Summary: Testicular germ cell tumors are highly heritable, and a large genome association study identified 22 novel loci, some of which may assist screening and treatment decisions through the study of PRS, reducing the risks in survivors. These findings highlight the interconnected nature of two known pathways that promote TGCT susceptibility, and implicate an additional biological pathway.

NATURE COMMUNICATIONS (2021)

Article Genetics & Heredity

The expressed mutational landscape of microsatellite stable colorectal cancers

Anita Sveen, Bjarne Johannessen, Ina A. Eilertsen, Bard Rosok, Marie Gulla, Peter W. Eide, Jarle Bruun, Kushtrim Kryeziu, Leonardo A. Meza-Zepeda, Ola Myklebost, Bjorn A. Bjornbeth, Rolf Skotheim, Arild Nesbakken, Ragnhild A. Lothe

Summary: Only a subset of mutations in microsatellite stable colorectal cancers were expressed, and the expressed mutation dose may provide an opportunity for more fine-tuned biomarker interpretations.

GENOME MEDICINE (2021)

Article Oncology

High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity

Susanne G. Kidd, Kristina T. Carm, Mari Bogaard, Linn Guro Olsen, Anne Cathrine Bakken, Marthe Lovf, Ragnhild A. Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I. Skotheim

Summary: In primary prostate cancer, high expression of SCHLAP1 serves as a robust prognostic biomarker for predicting biochemical recurrence and is associated with adverse clinicopathological characteristics. The heterogeneity of SCHLAP1 expression emphasizes the importance of analyzing multiple samples for determination of a patient's SCHLAP1 status.

NEOPLASIA (2021)

Article Biotechnology & Applied Microbiology

Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity

Jonas M. Stromme, Bjarne Johannessen, Susanne G. Kidd, Mari Bogaard, Kristina T. Carm, Xiaokang Zhang, Anita Sveen, Anthony Mathelier, Ragnhild A. Lothe, Ulrika Axcrona, Karol Axcrona, Rolf I. Skotheim

Summary: The study revealed extensive heterogeneity at the gene expression level in multifocal prostate cancer. Different malignant foci within the same patient showed similar levels of heterogeneity as tumors from different patients. Expression patterns linked to ETS status and extraprostatic extension were identified, and a set of 62 genes with low intrapatient heterogeneity and high interpatient heterogeneity were found, which could serve as prognostic biomarkers regardless of the sampled malignant focus.

CANCER GENE THERAPY (2022)

Editorial Material Urology & Nephrology

Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer

Rolf Skotheim, Ulrika Axcrona, Karol Axcrona

Summary: The research by Labanca et al strengthens the concept of an index tumor through the definition of aggressive molecular features. It suggests that molecular characterization will play a crucial role in radiogenomics development and guiding future treatment.

EUROPEAN UROLOGY (2022)

Article Endocrinology & Metabolism

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy

Anne M. A. Tryggestad, Karol Axcrona, Ulrika Axcrona, Iris Bigalke, Bjorn Brennhovd, Else M. Inderberg, Turid K. Honnashagen, Lisbeth J. Skoge, Guri Solum, Stein Saeboe-Larssen, Dag Josefsen, Richard W. Olaussen, Steinar Aamdal, Rolf I. Skotheim, Tor A. Myklebust, Dolores J. Schendel, Wolfgang Lilleby, Svein Dueland, Gunnar Kvalheim

Summary: This study aimed to reduce the risk of biochemical relapse in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy by administering personalized dendritic cell vaccines as adjuvant therapy. The results showed promising efficacy of the vaccine in reducing biochemical relapse incidence, as well as associations between baseline immune response and vaccine response during the vaccination period. Further investigation in larger cohorts is warranted to validate these findings and explore the potential of dendritic cell vaccines in post-surgical treatment of high-risk prostate cancer.

PROSTATE (2022)

Article Medicine, Research & Experimental

Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci

Jacqueline Fontugne, Peter Y. Cai, Hussein Alnajar, Bhavneet Bhinder, Kyung Park, Huihui Ye, Shaham Beg, Verena Sailer, Javed Siddiqui, Mirjam Blattner-Johnson, Jaclyn A. Croyle, Zohal Noorzad, Carla Calagua, Theresa Y. MacDonald, Ulrika Axcrona, Mari Bogaard, Karol Axcrona, Douglas S. Scherr, Martin G. Sanda, Bjarne Johannessen, Arul M. Chinnaiyan, Olivier Elemento, Rolf Skotheim, Mark A. Rubin, Christopher E. Barbieri, Juan Miguel Mosquera

Summary: Prostate cancer is a multifocal disease with distinct molecular subtypes. This study reveals the presence of inter- and intrafocal molecular heterogeneity in primary prostate cancer, with approximately 60% of multifocal specimens showing discordant molecular alterations between foci. Collision tumors, characterized by discrepant molecular status within a single focus, are identified in about 10% of the specimens. These findings highlight the complexity of molecular heterogeneity in prostate cancer and have important implications for future genomic studies.

JCI INSIGHT (2022)

Article Biochemistry & Molecular Biology

NRF2 drives an oxidative stress response predictive of breast cancer

Camilla Wolowczyk, Ulrike Neckmann, Miriam Ragle Aure, Martina Hall, Bjarne Johannessen, Sen Zhao, Rolf Skotheim, Sonja B. Andersen, Rosalie Zwiggelaar, Tonje S. Steigedal, Ole Christian Lingjaerde, Kristine Kleivi Sahlberg, Eivind Almaas, Geir Bjorkoy

Summary: In breast cancer patients, the NRF2 gene is continuously activated in metastatic cells and tumors, with corresponding upregulation of related genes. Depletion of NRF2 increases reactive oxygen species levels and severely reduces tumor formation and lung metastasis. A set of NRF2-regulated genes is elevated in breast cancer biopsies and can significantly improve prognosis prediction.

FREE RADICAL BIOLOGY AND MEDICINE (2022)

Article Pathology

Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer

Christian H. Bergsland, Marine Jeanmougin, Seyed H. Moosavi, Aud Svindland, Jarle Bruun, Arild Nesbakken, Anita Sveen, Ragnhild A. Lothe

Summary: This study investigated the prognostic heterogeneity of different regulatory T cell (Treg) populations in colorectal cancer (CRC) using multiplex fluorescence immunohistochemistry and digital image analysis. The results showed that Treg infiltration in tumors was strongly correlated with the overall amount of T cells and was associated with a favorable prognosis among CRC patients who underwent complete tumor resection. However, high expression of the activation marker CD25 in Tregs was independently associated with an adverse outcome. Moreover, spatial analysis revealed a significant proximity between Tregs and CD8+ cells, which was associated with a poor survival rate. These findings highlight the importance of multi-marker and spatial analysis in accurately predicting patient outcomes in CRC.

MODERN PATHOLOGY (2022)

Article Oncology

In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis

Susanne G. Kidd, Mari Bogaard, Kristina T. Carm, Anne Cathrine Bakken, Aase M. V. Maltau, Marthe Lovf, Ragnhild A. Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I. Skotheim

Summary: This study aimed to determine the prognostic value of candidate biomarkers transcriptional regulator ERG and related ETS family genes in prostate cancer, while considering tumor heterogeneity. The results showed that ERG protein has independent prognostic value in predicting biochemical and clinical recurrence of prostate cancer, and appears to have the greatest prognostic value for patients with Grade Groups 4-5.

MOLECULAR ONCOLOGY (2022)

Article Oncology

Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk

Chiara Grasso, Maja Popovic, Elena Isaevska, Fulvio Lazzarato, Valentina Fiano, Daniela Zugna, John Pluta, Benita Weathers, Kurt D'Andrea, Kristian Almstrup, Lynn Anson-Cartwright, D. Timothy Bishop, Stephen J. Chanock, Chu Chen, Victoria K. Cortessis, Marlene D. Dalgaard, Siamak Daneshmand, Alberto Ferlin, Carlo Foresta, Megan N. Frone, Marija Gamulin, Jourik A. Gietema, Mark H. Greene, Tom Grotmol, Robert J. Hamilton, Trine B. Haugen, Russ Hauser, Robert Karlsson, Lambertus A. Kiemeney, Davor Lessel, Patrizia Lista, Ragnhild A. Lothe, Chey Loveday, Coby Meijer, Kevin T. Nead, Jeremie Nsengimana, Rolf I. Skotheim, Clare Turnbull, David J. Vaughn, Fredrik Wiklund, Tongzhang Zheng, Andrea Zitella, Stephen M. Schwartz, Katherine A. McGlynn, Peter A. Kanetsky, Katherine L. Nathanson, Lorenzo Richiardi

Summary: This study found that genetic variants within the MTHFR gene are associated with the risk of testicular germ cell tumors (TGCT), potentially affecting the establishment of DNA methylation patterns. This finding suggests that the pathogenesis of TGCT may be related to the status of the folate cycle, and this relation could be partly due to hereditary factors.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer

Kristina T. Carm, Bjarne Johannessen, Mari Bogaard, Anne Cathrine Bakken, Aase Maltau, Andreas M. Hoff, Ulrika Axcrona, Karol Axcrona, Ragnhild A. Lothe, Rolf Skotheim

Summary: Our study highlights the spatio-temporal heterogeneity of multifocal prostate cancer and emphasizes the importance of testing a recent sample in genomics-based precision medicine for metastatic prostate cancer.

INTERNATIONAL JOURNAL OF CANCER (2023)

Meeting Abstract Pathology

GRIN3A-a novel biomarker identifying a subtype of intraductal prostate cancer (IDC-P)

M. Bogaard, J. M. Stromme, S. G. Kidd, B. Johannessen, A. C. Bakken, R. A. Lothe, K. Axcrona, R. I. Skotheim, U. Axcrona

VIRCHOWS ARCHIV (2022)

暂无数据